MX365261B - Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas. - Google Patents

Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas.

Info

Publication number
MX365261B
MX365261B MX2016015632A MX2016015632A MX365261B MX 365261 B MX365261 B MX 365261B MX 2016015632 A MX2016015632 A MX 2016015632A MX 2016015632 A MX2016015632 A MX 2016015632A MX 365261 B MX365261 B MX 365261B
Authority
MX
Mexico
Prior art keywords
bacterial infections
fused
treatment
heteroaromatic compounds
spirocyclic
Prior art date
Application number
MX2016015632A
Other languages
English (en)
Spanish (es)
Other versions
MX2016015632A (es
Inventor
Huband Michael
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of MX2016015632A publication Critical patent/MX2016015632A/es
Publication of MX365261B publication Critical patent/MX365261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2016015632A 2014-05-29 2015-05-27 Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas. MX365261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
PCT/IB2015/001585 WO2015181637A1 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
MX2016015632A MX2016015632A (es) 2017-04-25
MX365261B true MX365261B (es) 2019-05-27

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015632A MX365261B (es) 2014-05-29 2015-05-27 Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas.

Country Status (14)

Country Link
US (1) US10238661B2 (https=)
EP (1) EP3148546A1 (https=)
JP (1) JP6502387B6 (https=)
KR (1) KR20170007818A (https=)
CN (1) CN106659725A (https=)
AU (1) AU2015265620B2 (https=)
CA (1) CA2948438A1 (https=)
EA (1) EA033459B1 (https=)
IL (1) IL248838B (https=)
MX (1) MX365261B (https=)
PH (1) PH12016502271B1 (https=)
SG (2) SG10201906842WA (https=)
TW (1) TWI657818B (https=)
WO (1) WO2015181637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CA2606847A1 (en) 2005-05-09 2006-11-16 Warner-Lambert Company Llc Antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
CN102245605B (zh) * 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections

Also Published As

Publication number Publication date
IL248838B (en) 2020-05-31
TW201607537A (zh) 2016-03-01
TWI657818B (zh) 2019-05-01
US20180169104A1 (en) 2018-06-21
EA201692250A1 (ru) 2017-06-30
EP3148546A1 (en) 2017-04-05
PH12016502271A1 (en) 2017-02-06
JP6502387B2 (ja) 2019-04-17
JP2017516777A (ja) 2017-06-22
IL248838A0 (en) 2017-01-31
SG10201906842WA (en) 2019-08-27
US10238661B2 (en) 2019-03-26
EA033459B1 (ru) 2019-10-31
AU2015265620A1 (en) 2016-11-24
WO2015181637A1 (en) 2015-12-03
PH12016502271B1 (en) 2017-02-06
KR20170007818A (ko) 2017-01-20
MX2016015632A (es) 2017-04-25
JP6502387B6 (ja) 2019-05-29
AU2015265620B2 (en) 2020-04-09
SG11201609404SA (en) 2016-12-29
CN106659725A (zh) 2017-05-10
CA2948438A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
PH12019501079A1 (en) Magl inhibitors
WO2015112806A3 (en) Diaryl macrocycles as modulators of protein kinases
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
NZ763737A (en) 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
EP3596084A4 (en) 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
ZA201700110B (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
MX2016015761A (es) Derivados de amina de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK1248680A1 (zh) 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂
PH12016502271A1 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
CA3011077A1 (en) Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
BR112018016208A2 (pt) compostos heterocíclicos, em particular derivados 2-oxo-4,4,5,5,6,6,7,7-octahidrobenzoxazol, e seus usos como compostos antibacterianos
HK1236127A1 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
ZA201705052B (en) Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same
HK1231077A1 (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction

Legal Events

Date Code Title Description
FG Grant or registration